Drug intelligence / Profile preview

BEBT-756

Development stage: Preclinical
Lead developer: BeBetter Med
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BEBT-756 is a preclinical CNS-targeted dual-target small interfering RNA therapeutic being developed by BeBetter Med for Alzheimer's disease. It uses the company's peptide oligonucleotide conjugate CNS delivery platform and is intended to suppress amyloid beta precursor protein and microtubule-associated protein tau expression, addressing amyloid precursor protein and tau-related pathology in the central nervous system. ([bebettermed.com](https://www.bebettermed.com/))

Other names: BEBT 756BEBT756BEBT-756

Targets

MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on BEBT-756.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEBT-756.

Explore the full profile